In addition, olmutinib was launched in South Korea as a second-line treatment for patients with advanced or metastatic NSCLC with EGFR exon 20 p.T790M (T790M) mutation positivity in 2016 (Table 1) [20]. Here, EGFR is linked to non-small cell lung carcinoma.